Recce Pharmaceuticals Licenses R327G to Arrotex for AUS/NZ
Key points
- Recce Pharmaceuticals partners with Arrotex for R327G commercialization in AUS/NZ
- Arrotex to obtain exclusive rights for R327G in Australia and New Zealand
- Recce retains manufacturing rights and will receive profit share from sales
Full summary
Recce Pharmaceuticals Ltd (ASX: RCE) has announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd for RECCE® 327 topical gel (R327G) for the treatment of diabetic foot infections in Australia and New Zealand. Under the agreement, Arrotex will have exclusive rights to register and commercialize R327G, while Recce will remain the exclusive manufacturer and supplier. Recce will receive a significant profit share from gross margin on sales. The partnership combines Recce's anti-infective development platform with Arrotex's regulatory, market access, and commercial capabilities in the region. R327G is currently in Phase 3 clinical development for diabetic foot infections.
Summary generated by a large language model. Please interpret with care.